492 related articles for article (PubMed ID: 31858263)
21. Major CYP450 Polymorphism among Saudi Patients.
Almeman AA
Drug Metab Lett; 2021; 14(1):17-24. PubMed ID: 32703145
[TBL] [Abstract][Full Text] [Related]
22. Cytochrome P450 1A1, 2C9, 2C19, and 3A4 Polymorphisms Account for Interindividual Variability of Toxicological Drug Metabolism in Cynomolgus Macaques.
Uno Y; Uehara S; Murayama N; Yamazaki H
Chem Res Toxicol; 2018 Dec; 31(12):1373-1381. PubMed ID: 30412386
[TBL] [Abstract][Full Text] [Related]
23. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations.
Zuo J; Xia D; Jia L; Guo T
Pharmazie; 2012 Jul; 67(7):639-44. PubMed ID: 22888523
[TBL] [Abstract][Full Text] [Related]
24. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
[TBL] [Abstract][Full Text] [Related]
25. Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy.
Sun CJ; Li L; Li XY; Zhang WY; Liu XW
Arch Gynecol Obstet; 2018 Jul; 298(1):125-132. PubMed ID: 29789925
[TBL] [Abstract][Full Text] [Related]
26. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
[TBL] [Abstract][Full Text] [Related]
27. Applications of CYP450 testing in the clinical setting.
Samer CF; Lorenzini KI; Rollason V; Daali Y; Desmeules JA
Mol Diagn Ther; 2013 Jun; 17(3):165-84. PubMed ID: 23588782
[TBL] [Abstract][Full Text] [Related]
28. Genetic variability of CYP2D6, CYP2B6, CYP2C9 and CYP2C19 genes across the Italian Peninsula.
Carano F; Sarno S; De Fanti S; Serventi P; Bini C; Luiselli D; Pelotti S
Ann Hum Biol; 2018 Feb; 45(1):66-71. PubMed ID: 28971704
[TBL] [Abstract][Full Text] [Related]
29. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales.
Sistonen J; Fuselli S; Palo JU; Chauhan N; Padh H; Sajantila A
Pharmacogenet Genomics; 2009 Feb; 19(2):170-9. PubMed ID: 19151603
[TBL] [Abstract][Full Text] [Related]
31. Clinical pharmacogenetics and potential application in personalized medicine.
Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
[TBL] [Abstract][Full Text] [Related]
32. Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study.
Dodgen TM; Hochfeld WE; Fickl H; Asfaha SM; Durandt C; Rheeder P; Drögemöller BI; Wright GE; Warnich L; Labuschagne CD; van Schalkwyk A; Gaedigk A; Pepper MS
BMC Med Genet; 2013 Jan; 14():20. PubMed ID: 23356658
[TBL] [Abstract][Full Text] [Related]
33. Assessment of CYP2C9, CYP2C19, and CYP2D6 Polymorphisms in Allergic Patients with Chemical Sensitivity.
D'Attis S; Massari S; Mazzei F; Maio D; Vergallo I; Mauro S; Minelli M; Bozzetti MP
Int Arch Allergy Immunol; 2019; 179(3):173-186. PubMed ID: 30943525
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.
Lu S; Nand RA; Yang JS; Chen G; Gross AS
Eur J Clin Pharmacol; 2018 Mar; 74(3):285-296. PubMed ID: 29181698
[TBL] [Abstract][Full Text] [Related]
35. Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus.
Semiz S; Dujic T; Ostanek B; Prnjavorac B; Bego T; Malenica M; Marc J; Causevic A
Bosn J Basic Med Sci; 2010 Nov; 10(4):287-91. PubMed ID: 21108610
[TBL] [Abstract][Full Text] [Related]
36. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
37. Genomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans.
Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Sosa-Macías M; Terán E; López-López M; Rodeiro I; Moya GE; Calzadilla LR; Ramírez-Roa R; Grazina M; Estévez-Carrizo FE; Barrantes R; LLerena A;
Clin Pharmacol Ther; 2020 Jan; 107(1):257-268. PubMed ID: 31376146
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetic Testing for Analgesic Adverse Effects: Pediatric Case Series.
Manworren RC; Jeffries L; Pantaleao A; Seip R; Zempsky WT; Ruaño G
Clin J Pain; 2016 Feb; 32(2):109-15. PubMed ID: 25803758
[TBL] [Abstract][Full Text] [Related]
39. CYP2C9 and CYP2C19 Allele and Haplotype Distributions in Four Mestizo Populations from Western Mexico: An Interethnic Comparative Study.
Saldaña-Cruz AM; León-Moreno LC; Sánchez-Corona J; Santiago DA; Mendoza-Carrera F; Castro-Martínez XH; García-Zapién AG; Morán-Moguel MC; Flores-Martínez SE
Genet Test Mol Biomarkers; 2016 Nov; 20(11):702-709. PubMed ID: 27617498
[TBL] [Abstract][Full Text] [Related]
40. The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.
Liou YH; Lin CT; Wu YJ; Wu LS
J Hum Genet; 2006; 51(10):857. PubMed ID: 16924387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
